Tag Archives: First

FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Print this page HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults.1 This is… Read More »

What we're waiting to learn about President Trump's health one year after his first physical

As part of last year’s physical Trump requested then-White House physician Dr. Ronny Jackson to do something quite unusual, He asked him to administer a cognitive exam. These types of exams are not a routine part of a standard physical. Jackson, who was also the physician to President Barack Obama, said it was the first… Read More »